{"protocolSection": {"identificationModule": {"nctId": "NCT01012739", "orgStudyIdInfo": {"id": "CQAB149B2222"}, "secondaryIdInfos": [{"id": "2009-012600-48", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices", "officialTitle": "A Randomized, Partially-blinded, Single-dose, 4-way Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Maleate Administered Via the Concept1 Device or Via the Simoon Device"}, "statusModule": {"statusVerifiedDate": "2011-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-11-12", "studyFirstSubmitQcDate": "2009-11-12", "studyFirstPostDateStruct": {"date": "2009-11-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-22", "resultsFirstSubmitQcDate": "2011-07-22", "resultsFirstPostDateStruct": {"date": "2011-08-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-08-25", "lastUpdatePostDateStruct": {"date": "2011-08-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device. The study aimed to determine whether the novel formulation (Simoon) had a similar profile to that of the established formulation (Concept1).", "detailedDescription": "This study was double-blind with regards to the Concept1, where placebo for the lactose-blended indacaterol was available. However, with regards to the Simoon, neither the subject nor the investigator was blinded due to lack of a placebo to the PulmoSphere formulation. Hence, the overall designation of the study was partially-blind."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "QAB149", "indacaterol", "pulmonary function"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 35, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 \u03bcg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 \u03bcg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler", "Drug: Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler", "Drug: Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler", "Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler"]}, {"label": "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol 60 \u03bcg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 \u03bcg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 \u03bcg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler", "Drug: Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler", "Drug: Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler", "Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler"]}, {"label": "Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol 120 \u03bcg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 \u03bcg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 \u03bcg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler", "Drug: Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler", "Drug: Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler", "Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler"]}, {"label": "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 \u03bcg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 \u03bcg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 \u03bcg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler", "Drug: Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler", "Drug: Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler", "Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler", "description": "Indacaterol maleate 150 \u03bcg was provided in powder filled capsules with the Concept1 dry-powder inhaler.", "armGroupLabels": ["Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg"]}, {"type": "DRUG", "name": "Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler", "description": "Indacaterol 60 \u03bcg was provided in powder filled capsules with the Simoon dry-powder inhaler.", "armGroupLabels": ["Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg"]}, {"type": "DRUG", "name": "Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler", "description": "Indacaterol 120 \u03bcg was provided in powder filled capsules with the Simoon dry-powder inhaler.", "armGroupLabels": ["Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg"]}, {"type": "DRUG", "name": "Placebo to indacaterol via the Concept1 dry-powder inhaler", "description": "Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.", "armGroupLabels": ["Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose for each treatment.", "timeFrame": "Baseline and Day 1"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Peak Forced Expiratory Volume in 1 Second (FEV1) for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 4, 6, 8, and 12 hours post-dose in Day 1.", "timeFrame": "Baseline and Day 1"}, {"measure": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards at 5, 15, and 30 minutes; 1 hour, 1 hour 30 minutes; and 1, 2, 4, 6, 8, and 12 hours post-dose in Day 1.", "timeFrame": "From 5 minutes to 12 hours post-dose"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, and 4 hours post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time.", "timeFrame": "From 5 minutes to 4 hours post-dose for each treatment"}, {"measure": "Indacaterol Exposure (AUC[0-24 Hours]) for Each Treatment", "description": "All patients fasted for at least 10 hours prior to administration of study medication and continued to fast for at least 4 hours thereafter. Venous blood samples for pharmacokinetic evaluation were collected at 5, 10, 15, and 30 minutes; and 1, 2, 4, 8, and 24 hours post-dose in each treatment period and were analyzed using a LC-MS/MS assay. Area under the concentration-time curve up to 24 hours (AUC\\[0-24 hours\\]) was calculated from concentration-time data using non-compartmental analysis.", "timeFrame": "0 to 24 hours post-dose"}, {"measure": "Indacaterol Exposure (Cmax) for Each Treatment", "description": "All patients fasted for at least 10 hours prior to administration of study medication and continued to fast for at least 4 hours thereafter. Venous blood samples for pharmacokinetic evaluation were collected at 5, 10, 15, and 30 minutes; and 1, 2, 4, 8, and 24 hours post-dose in each treatment period and were analyzed using a LC-MS/MS assay. Maximum (peak) plasma drug concentration after drug administration (Cmax) was calculated from concentration-time data using non-compartmental analysis.", "timeFrame": "0 to 24 hours post-dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Patients with persistent asthma with a forced expiratory volume in 1 second (FEV1) \u2265 50%\n* Patients using inhaled corticosteroid (with or without long-acting beta agonist)\n\nExclusion criteria:\n\n* Asthma exacerbations in previous 6 months\n* Chronic obstructive pulmonary disease (COPD) or other pulmonary disease\n* Excessive use of short-acting beta agonists\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Belfast", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Novartis Investigative Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Indacaterol 150\u03bcg-placebo-Indacaterol 60\u03bcg-Indacaterol 120\u03bcg", "description": "In treatment period 1, patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 \u03bcg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 \u03bcg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "FG001", "title": "Indacaterol 60\u03bcg-Indacaterol 150\u03bcg-Indacaterol 120\u03bcg-placebo", "description": "In treatment period 1, patients received indacaterol 60 \u03bcg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 \u03bcg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 \u03bcg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Indacaterol 120\u03bcg-Indacaterol 60\u03bcg-placebo-Indacaterol 150\u03bcg", "description": "In treatment period 1, patients received indacaterol 120 \u03bcg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 \u03bcg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 \u03bcg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "FG003", "title": "Placebo-Indacaterol 120\u03bcg- Indacaterol 150\u03bcg- Indacaterol 60\u03bcg", "description": "In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 \u03bcg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 \u03bcg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 \u03bcg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Abnormal test procedure results", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Entire Study Population", "description": "The entire study population included all 4 treatment groups who received indacaterol 150 \u00b5g via the Concept1 dry-powder inhaler (DPI), indacaterol 60 \u00b5g via the Simoon DPI, indacaterol 120 \u00b5g via the Simoon DPI, and placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "35"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.6", "spread": "11.42"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose for each treatment.", "populationDescription": "Pharmacodynamic analysis set: All randomized patients that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI) only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.97", "spread": "0.695"}, {"groupId": "OG001", "value": "2.93", "spread": "0.688"}, {"groupId": "OG002", "value": "2.91", "spread": "0.734"}, {"groupId": "OG003", "value": "2.77", "spread": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peak Forced Expiratory Volume in 1 Second (FEV1) for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 4, 6, 8, and 12 hours post-dose in Day 1.", "populationDescription": "Pharmacodynamic analysis set: All randomized patients that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI) only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.19", "spread": "0.747"}, {"groupId": "OG001", "value": "3.15", "spread": "0.745"}, {"groupId": "OG002", "value": "3.15", "spread": "0.717"}, {"groupId": "OG003", "value": "2.96", "spread": "0.682"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards at 5, 15, and 30 minutes; 1 hour, 1 hour 30 minutes; and 1, 2, 4, 6, 8, and 12 hours post-dose in Day 1.", "populationDescription": "Pharmacodynamic analysis set: All randomized patients that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "From 5 minutes to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI) only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.80", "spread": "7.614"}, {"groupId": "OG001", "value": "8.22", "spread": "7.990"}, {"groupId": "OG002", "value": "7.50", "spread": "7.370"}, {"groupId": "OG003", "value": "7.93", "spread": "7.747"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose for Each Treatment", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, and 4 hours post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time.", "populationDescription": "Pharmacodynamic analysis set: All randomized patients that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "From 5 minutes to 4 hours post-dose for each treatment", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI) only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.03", "spread": "0.743"}, {"groupId": "OG001", "value": "2.96", "spread": "0.732"}, {"groupId": "OG002", "value": "2.99", "spread": "0.722"}, {"groupId": "OG003", "value": "2.78", "spread": "0.651"}]}]}]}, {"type": "SECONDARY", "title": "Indacaterol Exposure (AUC[0-24 Hours]) for Each Treatment", "description": "All patients fasted for at least 10 hours prior to administration of study medication and continued to fast for at least 4 hours thereafter. Venous blood samples for pharmacokinetic evaluation were collected at 5, 10, 15, and 30 minutes; and 1, 2, 4, 8, and 24 hours post-dose in each treatment period and were analyzed using a LC-MS/MS assay. Area under the concentration-time curve up to 24 hours (AUC\\[0-24 hours\\]) was calculated from concentration-time data using non-compartmental analysis.", "populationDescription": "Pharmacokinetic analysis set: All randomized patients with evaluable pharmacokinetic data, ie, from which at least one pharmacokinetic parameter could be determined and sampling time information was available, from at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*hr/mL", "timeFrame": "0 to 24 hours post-dose", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1119.2", "spread": "379.1"}, {"groupId": "OG001", "value": "435.8", "spread": "245.7"}, {"groupId": "OG002", "value": "849.4", "spread": "272.7"}]}]}]}, {"type": "SECONDARY", "title": "Indacaterol Exposure (Cmax) for Each Treatment", "description": "All patients fasted for at least 10 hours prior to administration of study medication and continued to fast for at least 4 hours thereafter. Venous blood samples for pharmacokinetic evaluation were collected at 5, 10, 15, and 30 minutes; and 1, 2, 4, 8, and 24 hours post-dose in each treatment period and were analyzed using a LC-MS/MS assay. Maximum (peak) plasma drug concentration after drug administration (Cmax) was calculated from concentration-time data using non-compartmental analysis.", "populationDescription": "Pharmacokinetic analysis set: All randomized patients with evaluable pharmacokinetic data, ie, from which at least one pharmacokinetic parameter could be determined and sampling time information was available, from at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "0 to 24 hours post-dose", "groups": [{"id": "OG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received Indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received Indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "150.5", "spread": "30.4"}, {"groupId": "OG001", "value": "95.2", "spread": "57.3"}, {"groupId": "OG002", "value": "141.7", "spread": "55.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety population included all randomized patients that received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Indacaterol 150 \u03bcg", "description": "Patients received indacaterol 150 \u03bcg via the Concept1 dry-powder inhaler (DPI)only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 33, "otherNumAffected": 19, "otherNumAtRisk": 33}, {"id": "EG001", "title": "Indacaterol 60 \u03bcg", "description": "Patients received Indacaterol 60 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 33, "otherNumAffected": 16, "otherNumAtRisk": 33}, {"id": "EG002", "title": "Indacaterol 120 \u03bcg", "description": "Patients received indacaterol 120 \u03bcg via the Simoon dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 34, "otherNumAffected": 21, "otherNumAtRisk": 34}, {"id": "EG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol via the Concept1 dry-powder inhaler only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 11, "otherNumAtRisk": 35}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 35}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 33}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 35}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 33}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 34}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 35}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M13031", "name": "Oxymetazoline", "relevance": "LOW"}, {"id": "M13561", "name": "Phenylephrine", "relevance": "LOW"}, {"id": "M245808", "name": "Maleic acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}